Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $8.13 Million - $10.1 Million
20,700 Added 53.49%
59,400 $27.8 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $27.4 Million - $29.9 Million
-67,100 Reduced 63.42%
38,700 $16.2 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $13.2 Million - $15.9 Million
38,600 Added 57.44%
105,800 $43 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $21.7 Million - $24.3 Million
-69,100 Reduced 50.7%
67,200 $23.6 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $14.8 Million - $16.8 Million
52,100 Added 61.88%
136,300 $42.9 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $8.49 Million - $9.55 Million
29,700 Added 54.5%
84,200 $24.3 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $20.6 Million - $23 Million
-75,400 Reduced 58.04%
54,500 $15.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.